Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia [0.03%]
用于B细胞慢性淋巴细胞性白血病适应性治疗的工程T细胞
Philipp Koehler,Patrick Schmidt,Andreas A Hombach et al.
Philipp Koehler et al.
B-cell chronic lymphocytic leukaemia (B-CLL) remains an incurable disease due to the high risk of relapse, even after complete remission, raising the need to control and eliminate residual tumor cells in long term. Adoptive T cell therapy w...
Pinelopi Argyriou,Panagiota Economopoulou,Sotirios Papageorgiou
Pinelopi Argyriou
Despite the fact that the majority of lymphomas initially respond to treatment, many patients relapse and die from disease that is refractory to current regimens. The need for new treatment strategies in lymphomas has led to the investigati...
Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy [0.03%]
染色体重塑因子突变与髓系肿瘤的表观遗传学靶向治疗
Amir T Fathi,Omar Abdel-Wahab
Amir T Fathi
In the recent years, the discovery of a series of mutations in patients with myeloid malignancies has provided insight into the pathogenesis of myelodysplastic syndromes (MDSs), myeloproliferative neoplasms (MPNs), and acute myeloid leukemi...
Masahiko Ito,Hideki Kusunoki,Keiko Mochida et al.
Masahiko Ito et al.
Hepatitis C virus (HCV) has been recognized as a major cause of chronic liver diseases worldwide. It has been suggested that HCV infects not only hepatocytes but also mononuclear lymphocytes including B cells that express the CD81 molecule,...
Yutaka Tsutsumi,Shinichi Ito,Reiki Ogasawara et al.
Yutaka Tsutsumi et al.
Hepatitis C virus (HCV) is one of the viruses known to cause hepatic cancer. HCV is also believed to be involved in malignant lymphoma. In this paper, we investigated characteristics of malignant lymphoma cases that were anti-HCV antibody (...
The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future [0.03%]
经典霍奇金淋巴瘤的过去、现在和未来的诊治策略
S E Richardson,C McNamara
S E Richardson
The management of classical Hodgkin's lymphoma (CHL) is a success story of modern multi-agent haemato-oncology. Prior to the middle of the twentieth century CHL was fatal in the majority of cases. Introduction of single agent radiotherapy (...
Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma [0.03%]
ABVD化疗所致霍奇金淋巴瘤患者中性粒细胞减少和中性粒细胞减少相关并发症的关系
Bhanu Vakkalanka,Brian K Link
Bhanu Vakkalanka
A combination of Adriamycin (a.k.a. Doxorubicin), Bleomycin, Vinblastine, and Dacarbazine (ABVD) is the most commonly used chemotherapy regime for Hodgkin lymphoma. This highly effective treatment is associated with a significant risk of ne...
Highly Elevated Serum Hepcidin in Patients with Acute Myeloid Leukemia prior to and after Allogeneic Hematopoietic Cell Transplantation: Does This Protect from Excessive Parenchymal Iron Loading? [0.03%]
急性髓系白血病患者allo-HSCT前后血液中肝肽素水平升高：这是否可以防止过多的实质铁负荷？
Ann-Kathrin Eisfeld,Mark Westerman,Rainer Krahl et al.
Ann-Kathrin Eisfeld et al.
Hepcidin is upregulated by inflammation and iron. Inherited (HFE genotype) and treatment-related factors (blood units (BU), Iron overload) affecting hepcidin (measured by C-ELISA) were studied in 42 consecutive patients with AML prior to an...
Use of rituximab in autoimmune hemolytic anemia associated with non-hodgkin lymphomas [0.03%]
自身免疫性溶血性贫血伴发非霍奇金淋巴瘤的利妥昔单抗治疗
Claudio Fozza,Maurizio Longinotti
Claudio Fozza
The association between non-Hodgkin lymphomas and autoimmune disorders is a well-known event. Also autoimmune hemolytic anemia (AHA), although much more frequent in patients with chronic lymphocytic leukemia (CLL), has been described in thi...
Sukhinder K Sandhu,Carlo M Croce,Ramiro Garzon
Sukhinder K Sandhu
The recent discovery of microRNAs (miRNAs) has introduced a new layer of complexity to the process of gene regulation. MiRNAs are essential for cellular function, and their dysregulation often results in disease. Study of miRNA expression a...